Dr Konstantinos Tzelepis

University of Cambridge

University departments: 
Wellcome Trust MRC Cambridge Stem Cell Institute
Milner Therapeutics Institute

Position: Group Leader
Personal home page:
Email:   kt404@cam.ac.uk

PubMed journal articles - click here

Research description: 
Our group is uncovering epigenetic and epitranscriptomic mechanisms that are implicated in cancer initiation and maintenance. Our work has previously identified several novel RNA-binding/modifying proteins that are essential for cancer cell survival, including the RNA methyltransferases METTL3 and METTL1 as well as the splicing kinase SRPK1. 
Research Programme or Virtual Institute: 
Haematological Malignancies Virtual Institute
Strategic Resources: 
The Milner Therapeutics Institute and Consortium
Tumour type interests: 
Brain and central nervous system
Colorectal
Leukemia
Lung
Pancreas
Small intestine
Keywords: 

CRISPR Mutagenesis

Genetic Screening

Novel Therapeutics

Technology Development


Key publications: 
  1. Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021 
  2. Orellana et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell 2021
  3. Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020